DeutschEnglish

Clinical Immunology


Members (alphabetically sorted):

Michael Fischer, Univ.-Klinik für Blutgruppenserologie und Transfusionsmedizin, Wien
Andreas Heitger, St.Anna Kinderspital, Wien
Gerald Höfler, Institut für Pathologie der Karl-Franzens-Universität Graz
Hans Lassmann, Institut für Hirnforschung der Universität Wien
Eveline Schretter-Irschick, Univ.-Klinik für Augenheilkunde, Innsbruck
Josef Smolen, Univ.-Klinik für Innere Medizin III, Wien
Georg Stingl, Univ.-Klinik für Dermatologie, Wien
Gernot P. Tilz, Medizinische Universitätsklinik, Graz
Georg Wick, Institut für Pathophysiologie der Universität Innsbruck,
Hermann Wolf, Immunologische Tagesklinik, Wien
Gerhard Zlabinger, Institut für Immunologie der Universität Wien

The Committee for professional policy and education in clinical immunology (work group: clinical immunology of ÖGAI) was created at the occasion of the annual general assembly 2001. The purpose was to create a forum for clinical-immunological questions. So far numerous meetings of this group have taken place. Regarding education the group sees its primary goal in creating guidelines containing opinions to clinical-immunological questions with regards to diagnosis and therapy in particular immune-mediated diseases. Doctors of all specializations are meant to be informed about new developments in the field of clinical immunology. This group is also meant to function as ÖGAI's mouthpiece towards patients, media and authorities with regard to clinical-immunological questions.


The first position paper (in planning) is a  statement on the basic principles, modes of action, indications and side-effects of a therapy with human immunoglobulin compounds, in particular regarding off-label usage of intravenously adminstered  compounds (IVIG). The subject of the  indication regarding off-label administration of IVIG (i.e. the therapeutic usage of IVIG outside of indications authorized by the authorities) is of importance in cases when shortages result due to supplies of biological medication from human immunoglobulin in principle not being endlessly available. It is a product that is extracted from the plasma of healthy donors by means of a complex manufacturing process.

Subject of another position paper of this working group shows the diagnostic processes used in clinical immunology. It focuses, in particular, on the siginificance, value and limits within diagnostics, differential diagnostics and progression of mainly immune-mediated diseases. A special focus has been put on rational and well-founded use of speciai tests, in  particular, the expert interpretation  of the results of diagnostic use of immunological testing procedures.

 




 
 


Wir thank the supporting members:


alkabello
allergopharma
astrazeneca
Shire
bd
affymetrix_bioscience
biomedica
eubio
gsk
meda
morpho
novartis
thermofisher
szabo